medigraphic.com
ISSN 0001-0944 (Print)
Órgano Oficial de la Asociación Dental Mexicana

2021, Number 1

<< Back Next >>

Rev ADM 2021; 78 (1)

Knowledge and awareness of physicians about bisphosphonate-related osteonecrosis of the jaws.

Vinitzky-Brener I, Ibáñez-Mancera NG, Álvarez JAP, Serra-Rico LJ, Carrasco RCA, Fernández PR, Martínez BD

Language: Spanish
References: 17
Page: 28-32
PDF size: 149.30 Kb.


ABSTRACT

Objectives: To evaluate the knowledge and awareness of physicians about bisphosphonate-related osteonecrosis of the jaws. Material and methods: A cross-sectional survey was carried out among general practitioners and specialized physicians to determine their knowledge and awareness of bisphosphonate-related osteonecrosis of the jaws. Results: Of the 475 interviewed general practitioners and specialized physicians, 210 (44.2%) claimed to prescribe bisphosphonates. A total of 58.1% of these physicians did not refer their patients to the dentist for the elimination of risk factors, despite the fact that 61.8% of them reported knowledge of the adverse reactions of these drugs. Thirty-six physicians (17.4%) had seen some patient with bisphosphonate-related osteonecrosis of the jaws. A total of 37% of the physicians that prescribed drugs considered it not necessary to refer patients to the dentist. Conclusions: Bisphosphonate prescription is increasingly common in medical practice, and physicians must have adequate knowledge of the adverse reactions of these drugs in order to ensure opportune patient referral to the dentist, educate their patients, and avoid complications such as bisphosphonate-related osteonecrosis of the jaws.


REFERENCES

  1. Gavaldá C, Bagán JV. Concept, diagnosis and classification of bisphosponate-associated osteonecrosis of the jaws. A review of the literature. Med Oral Patol Oral Cir Bucal. 2016; 2 (3): e260-e270.

  2. Moro-Alvarez MJ, Díaz-Curiel M. Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis. Clin Interv Aging. 2008; 3 (2): 227-232.

  3. He Y, Huang Y, Huang Z, Jiang Y, Sun X, Shen Y et al. Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer. J Control Release. 2017; 264: 76-88.

  4. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61 (9): 1115-1117.

  5. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62 (5): 527-534.

  6. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65 (3): 369-376.

  7. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009; 67 (5 Suppl): 2-12.

  8. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72 (10): 1938-1956.

  9. Manfredi M, Mergoni G, Goldoni M, Salvagni S, Merigo E, Meleti M et al. A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors. Med Oral Patol Oral Cir Bucal. 2017; 22 (3): e342-e348.

  10. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015; 30 (1): 3-23.

  11. Yoo JY, Park YD, Kwon YD, Kim DY, Ohe JY. Survey of Korean Dentist on the awareness on bisphosphonate-related osteonecrosis of the jaws. J Investig Clin Dent. 2010; 1 (2): 90-95.

  12. Alhussain A, Peel S, Dempster L, Clokie C, Azarpazhooh A. Knowledge, practices, and opinions of Ontario dentists when treating patients receiving bisphosphonates. J Oral Maxillofac Surg. 2015; 73 (6): 1095-1105.

  13. Vinitzky-Brener I, Ibáñez-Mancera NG, Aguilar-Rojas AM, Álvarez-Jardón AP. Knowledge of bisphosphonate-related osteonecrosis of the Jaws among Mexican dentists. Med Oral Patol Oral Cir Bucal. 2017; 22 (1): e84-e87.

  14. Al-Mohaya MA, Al-Khashan HI, Mishriky AM, Al-Otaibi LM. Physicians' awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med J. 2011; 32 (8): 830-835.

  15. El Osta L, El Osta B, Lakiss S, Hennequin M, El Osta N. Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians. Support Care Cancer. 2015; 23 (9): 2825-2831.

  16. Kim JW, Jeong SR, Kim SJ, Kim Y. Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw. BMC Oral Health. 2016; 16 (1): 92.

  17. Senturk MF, Cimen E, Tuzuner Oncul AM, Cambazoglu M. Oncologists awareness about bisphosphonate related osteonecrosis of the jaws. J Pak Med Assoc. 2016; 66 (7): 880-883.




2020     |     www.medigraphic.com